According to clients interviewed by Intellectual Asset Management (IAM) magazine, Allen provides “advice that is timely, contextually relevant and extremely useful” and his “ability to take complex scientific and legal issues and distil them into advice and guidance that we can truly act upon” is commendable. His more than 23 years of experience as a patent attorney and prior experience as a pharmaceutical chemist at DuPont Merck Pharmaceuticals and Smithkline Beecham gives him the ability to “very quickly pick up on the technology”.
Clients hire Allen to identify and execute strategies to protect key commercial products and bring lucrative products to market in areas heavily patented by competitors. With an extensive litigation background, Allen is also frequently retained to evaluate the strength of patents under consideration for licensing, acquisition, or investment and has provided opinions on patents protecting products with sales in excess of $1 billion.
Allen was president of the Licensing Executives Society for USA & Canada, in 2006-2007 and the president and chairman of the Board of Governors for Certified Licensing Professionals (CLP). Allen serves as the managing shareholder of the firm's Research Triangle Park, N.C., office and previously served a two-year term on the firm’s board of directors.
Allen’s work includes post grant litigation before the U.S. Patent and Trademark Office, freedom-to-operate studies, due diligence review, infringement/validity studies, licensing, paragraph IV litigation, reexamination, and patent preparation/prosecution in the areas of chemistry, pharmaceuticals, biochemistry, biotechnology and medical devices. His representative clients are active in small molecule pharmaceuticals, crop protection, biologics, vaccines, medical devices, ocular medications/implants, green technologies, nuclear power and advanced materials.